BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Golubovskaya V, Zhou H, Li F, Valentine M, Sun J, Berahovich R, Xu S, Quintanilla M, Ma MC, Sienkiewicz J, Huang Y, Wu L. Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma. Cancers (Basel) 2021;13:981. [PMID: 33652767 DOI: 10.3390/cancers13050981] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Li X, Feng Y, Shang F, Yu Z, Wang T, Zhang J, Song Z, Wang P, Shi B, Wang J. Characterization of the Therapeutic Effects of Novel Chimeric Antigen Receptor T Cells Targeting CD38 on Multiple Myeloma. Front Oncol 2021;11:703087. [PMID: 34513682 DOI: 10.3389/fonc.2021.703087] [Reference Citation Analysis]
2 Barros LRC, Couto SCF, da Silva Santurio D, Paixão EA, Cardoso F, da Silva VJ, Klinger P, Ribeiro PDAC, Rós FA, Oliveira TGM, Rego EM, Ramos RN, Rocha V. Systematic Review of Available CAR-T Cell Trials around the World. Cancers 2022;14:2667. [DOI: 10.3390/cancers14112667] [Reference Citation Analysis]
3 Furqan F, Shah NN. Bispecific CAR T-cells for B-cell malignancies. Expert Opin Biol Ther 2022. [PMID: 35653589 DOI: 10.1080/14712598.2022.2086043] [Reference Citation Analysis]
4 Golubovskaya V, Zhou H, Li F, Berahovich R, Sun J, Valentine M, Xu S, Harto H, Sienkiewicz J, Huang Y, Wu L. Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma. Biomedicines 2021;9:1422. [PMID: 34680541 DOI: 10.3390/biomedicines9101422] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Miazek-Zapala N, Slusarczyk A, Kusowska A, Zapala P, Kubacz M, Winiarska M, Bobrowicz M. The "Magic Bullet" Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era. Cells 2021;10:1511. [PMID: 34203935 DOI: 10.3390/cells10061511] [Reference Citation Analysis]